WISDOM: history and early demise - was it inevitable?
In 1989, the UK Medical Research Council (MRC) agreed that, if feasible, a randomized controlled trial to assess the long-term risks and benefits of hormone replacement therapy (HRT) was a priority. Feasibility work began in 1990 and demonstrated that a large-scale multicenter trial was possible. An application for funding for a main trial was submitted to MRC in 1993 and, after extensive review, funding was released in late 1996. Set-up work for the trial - the Women's International Study of long Duration Oestrogen after Menopause (WISDOM) - began in 1997 with recruitment in 1999. In October 2002, following the early discontinuation of one arm of the US Women's Health Initiative HRT trial, the MRC decided to stop the WISDOM trial. This article, by the principal UK investigators of WISDOM, sets out the background and history of the trial.
Vickers
M
M
Medical Research Council General Practice Research Framework, MRC Clinical Trials Unit, London, UK.
Meade
T
T
Darbyshire
J
J
D026661:Clinical Trials Data Monitoring Committees; D015914:Estrogen Replacement Therapy; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008402:Mass Media; D017063:Outcome Assessment, Health Care; D018579:Patient Selection; D017698:Postmenopause; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D012109:Research Support as Topic; D006113:United Kingdom; D016387:Women's Health